Vanda Pharmaceuticals Inc.VNDANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +22.76% | +17.48% | +5.43% | +4.19% | +18.06% |
| Gross Profit Growth | +26.15% | +21.01% | +10.75% | +4.60% | +18.19% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -3986.13% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -3908.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -3908.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.29% | +1.35% | +1.33% | +1.33% | +1.05% |
| Weighted Average Shares Diluted Growth | +1.16% | +1.35% | +1.33% | +1.33% | +1.05% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -537.93% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | -544.10% | +0.00% | +0.00% |
| Receivables Growth | +46.05% | +37.90% | +21.49% | +7.47% | +18.22% |
| Inventory Growth | +60.44% | +27.19% | +27.77% | +47.65% | +26.52% |
| Asset Growth | +0.55% | +1.20% | -3.18% | -4.09% | -6.82% |
| Book Value per Share Growth | -1.62% | -2.48% | -7.22% | -11.53% | -14.79% |
| Debt Growth | -19.36% | +31.43% | +31.61% | +38.04% | -21.57% |
| R&D Expense Growth | +1.06% | -18.48% | +68.82% | +31.98% | +34.50% |
| SG&A Expenses Growth | +51.71% | +66.36% | +66.47% | +63.69% | +60.42% |